Vascular endothelial growth factor receptor 3 messenger RNA (VEGFR-3 mRNA)

Vascular endothelial growth factor receptor 3 (VEGFR-3) mRNA is the transcript of the FLT4 gene, which encodes a receptor tyrosine kinase essential for lymphangiogenesis and the maintenance of lymphatic vessels (UniProt P35916). In the context of therapeutic development, this mRNA is targeted by RNA interference (RNAi) molecules, such as small interfering RNAs (siRNAs), and antisense oligonucleotides (ASOs) to prevent the synthesis of the VEGFR-3 protein (PubMed: 15150579). By silencing this transcript, researchers aim to inhibit the formation of new lymphatic vessels, a process frequently exploited by solid tumors to facilitate regional lymph node metastasis (PubMed: 21833014). Beyond oncology, targeting VEGFR-3 mRNA is explored for treating ocular conditions like corneal neovascularization and inflammatory diseases where pathological lymphangiogenesis occurs. While small molecule inhibitors and monoclonal antibodies targeting the VEGFR-3 protein are more common in clinical practice, mRNA-targeted approaches offer high specificity and the potential to overcome resistance mechanisms associated with protein-level inhibition. This target is particularly relevant for precision medicine strategies that require the complete knockdown of the receptor rather than just the inhibition of its kinase activity.

Other names

FLT4 mRNAFms-related tyrosine kinase 4 mRNAVascular endothelial growth factor receptor 3 transcript

RNA interference or antisense inhibition leading to mRNA degradation and reduced protein translation